Literature DB >> 25421473

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens.

Berthony Deslouches1, Jonathan D Steckbeck1, Jodi K Craigo1, Yohei Doi2, Jane L Burns3, Ronald C Montelaro4.   

Abstract

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25421473      PMCID： PMC4335883          DOI： 10.1128/AAC.03937-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Antimicrobial peptides: key components of the innate immune system.

Authors:  Mukesh Pasupuleti; Artur Schmidtchen; Martin Malmsten
Journal:  Crit Rev Biotechnol       Date:  2011-11-11       Impact factor: 8.429

Review 2.  Impact of LL-37 on anti-infective immunity.

Authors:  Dawn M E Bowdish; Donald J Davidson; Y Elaine Lau; Ken Lee; Monisha G Scott; Robert E W Hancock
Journal:  J Leukoc Biol       Date:  2004-11-29       Impact factor: 4.962

Review 3.  An evidence-based clinical guideline for antibiotic prophylaxis in spine surgery.

Authors:  William O Shaffer; Jamie L Baisden; Robert Fernand; Paul G Matz
Journal:  Spine J       Date:  2013-08-27       Impact factor: 4.166

Review 4.  [Mobile ISCR elements: structure, functions, and role in the emergence, increasing and spreading of blocks of bacterial genes of multiple antibiotic resistance].

Authors:  T S Il'ina
Journal:  Mol Gen Mikrobiol Virusol       Date:  2012

5.  Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Authors:  Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy.

Authors:  E J Bow
Journal:  J Antimicrob Chemother       Date:  2013-01-08       Impact factor: 5.790

7.  Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens.

Authors:  Berthony Deslouches; Jonathan D Steckbeck; Jodi K Craigo; Yohei Doi; Timothy A Mietzner; Ronald C Montelaro
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia.

Authors:  Berthony Deslouches; Ivan A Gonzalez; Dilhari DeAlmeida; Kazi Islam; Chad Steele; Ronald C Montelaro; Timothy A Mietzner
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii.

Authors:  Brooke A Napier; Eileen M Burd; Sarah W Satola; Stephanie M Cagle; Susan M Ray; Patrick McGann; Jan Pohl; Emil P Lesho; David S Weiss
Journal:  mBio       Date:  2013-05-21       Impact factor: 7.867

10.  Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2.

Authors:  Shruti M Paranjape; Thomas W Lauer; Ronald C Montelaro; Timothy A Mietzner; Neeraj Vij
Journal:  F1000Res       Date:  2013-02-08
View more
  50 in total

1.  Synergistic Biophysical Techniques Reveal Structural Mechanisms of Engineered Cationic Antimicrobial Peptides in Lipid Model Membranes.

Authors:  Frank Heinrich; Aria Salyapongse; Akari Kumagai; Fernando G Dupuy; Karpur Shukla; Anja Penk; Daniel Huster; Robert K Ernst; Anna Pavlova; James C Gumbart; Berthony Deslouches; Y Peter Di; Stephanie Tristram-Nagle
Journal:  Chemistry       Date:  2020-04-28       Impact factor: 5.236

2.  Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.

Authors:  Éanna Forde; André Schütte; Emer Reeves; Catherine Greene; Hilary Humphreys; Marcus Mall; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

4.  Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine.

Authors:  Berthony Deslouches; Mary L Hasek; Jodi K Craigo; Jonathan D Steckbeck; Ronald C Montelaro
Journal:  J Med Microbiol       Date:  2016-04-05       Impact factor: 2.472

5.  Stability and efficacy of synthetic cationic antimicrobial peptides nebulized using high frequency acoustic waves.

Authors:  Ying Wang; Amgad R Rezk; Jasmeet Singh Khara; Leslie Y Yeo; Pui Lai Rachel Ee
Journal:  Biomicrofluidics       Date:  2016-06-07       Impact factor: 2.800

6.  Branched Peptides: Acridine and Boronic Acid Derivatives as Antimicrobial Agents.

Authors:  Jessica E Wynn; Wenyu Zhang; Joseph O Falkinham; Webster L Santos
Journal:  ACS Med Chem Lett       Date:  2017-07-12       Impact factor: 4.345

7.  Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37.

Authors:  Qiao Lin; Berthony Deslouches; Ronald C Montelaro; Y Peter Di
Journal:  Int J Antimicrob Agents       Date:  2018-05-10       Impact factor: 5.283

8.  Elastic behavior of model membranes with antimicrobial peptides depends on lipid specificity and d-enantiomers.

Authors:  Akari Kumagai; Fernando G Dupuy; Zoran Arsov; Yasmene Elhady; Diamond Moody; Robert K Ernst; Berthony Deslouches; Ronald C Montelaro; Y Peter Di; Stephanie Tristram-Nagle
Journal:  Soft Matter       Date:  2019-02-20       Impact factor: 3.679

9.  Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

Authors:  Jeffrey A Melvin; Ronald C Montelaro; Jennifer M Bomberger
Journal:  Expert Rev Anti Infect Ther       Date:  2016-09-22       Impact factor: 5.091

Review 10.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.